Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.82 |
| ▸ | HTR3A | P46098 | 8/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616390 | 1.00 | HRH3 (0.82) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375371 | 0.90 | HRH3 (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375368 | 0.90 | HRH3 (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375211 | 0.89 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375210 | 0.89 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375351 | 0.85 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1375354 | 0.85 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1372486 | 0.81 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1376832 | 0.81 | HTR3A (1.00) | HRH3HTR3AKCNH2 | |
| SCHEMBL1372483 | 0.81 | HTR3A (1.00) | HRH3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HTR3A 15/4885KCNH2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.